Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pembrolizumab with Carboplatin and Nab-Paclitaxel for mTNBC
NCT03121352Phase 2Completed
- Sponsor
- Case Comprehensive Cancer Center
- Start
- May 2017
- Primary completion
- Feb 2022
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of pembrolizumab in triple-negative breast cancer (TNBC), sponsored by Case Comprehensive Cancer Center. Started May 2017; status: completed.
02
Drugs
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT03121352.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03121352.